Orion Corporation

ORNAV.HE

Finland

Orion Corporation is a leading Nordic pharmaceutical company founded in 1917 and headquartered in Espoo, Finland. The company operates through three main business areas: proprietary products, specialty products, and fermion (contract manufacturing). Orion has a strong presence in neurology, oncology, and critical care, with established commercial operations across Europe and expanding global reach.

orion.fi

ORNAV.HE · Stock Price

USD 67.40+13.40 (+24.81%)

Market Cap: $2.4B

Historical price data

AI Company Overview

OncologyNeurologyCritical CareParkinson's DiseaseSedation

Technology Platform

Diversified pharmaceutical platform focused on proprietary drug development, specialty pharmaceuticals, and contract manufacturing with expertise in CNS disorders, oncology, and critical care medications.

Pipeline

112

112 drugs in pipeline18 in Phase 3

Drug	Indication	Stage
Hydroxychloroquine + Placebo	Myocardial Infarction	Approved
Levosimendan + Placebo	Heart Failure	Approved
Methotrexate	Spondylarthropathies	Approved
Dexmedetomidine	ICU Sedation	Approved
Levosimendan + Placebo	Heart Failure	Approved

Opportunities

Growth opportunities include expanding Nubeqa's global market penetration, developing new indications for existing compounds, and leveraging Fermion's manufacturing capabilities for additional contract manufacturing partnerships.

Risk Factors

Key risks include patent cliff challenges for mature products, intense competition in oncology markets, and regulatory complexities across multiple international markets where the company operates.

Competitive Landscape

Orion competes with large pharma companies like Janssen and Pfizer in oncology, and AbbVie in Parkinson's disease, while differentiating through Nordic market expertise, manufacturing capabilities, and focused therapeutic area specialization.